CREATE


Protocolnummer:
NL40334.058.12

Ziekenhuizen:
Erasmus Medisch Centrum Rotterdam
Leids Universitair Medisch Centrum
RadboudUMC Nijmegen

Titel:
Cross-tumoral Phase 2 clinical trial exploring Crizotinib (PF-02341066) in patients with advanced tumours induced by causal alterations of either ALK or MET

Behandeling:
A biomarker-driven multi-tumor Phase II multicentric trial investigating the activity of the single agent crizotinib (Xalkori®).

Stadium:

Belangrijkste in/exclusiecriteria:
In: Local diagnosis of locally advanced and/or metastatic malignant tumor- Papillary renal cell carcinoma type 1 (PRCC), Target lesion of at least 20 mm (or 10 mm on spiral CT scans), Minimum age 15 years, Adequate hematological renal and liver function. Ex: Carcinomatous meningitis or leptomeningeal disease, Treatment with any other investigational drug within the past 4 weeks , Prior therapy directly targeting ALK and/or MET, previous treatment with crizotinib, Acute or chronic severe gastrointestinal conditions, Current congestive heart failure, Ongoing cardiac dysrhythmias

Contactpersoon:

Alle niercelcarcinoom trials